Results 61 to 70 of about 410,880 (314)

Advancing the legal rights of people with advanced breast cancer: a global expert review and call-to-action for 2025–2035 (Goal 10)

Breast
A diagnosis of advanced breast cancer (ABC) can be life-altering, presenting challenges that extend far beyond the clinical domain. Among these challenges is the ability to continue or return to work, a decision often influenced by financial necessity ...
Sarah McHutchison, Tarishi Desai, Hayley Jones, Georgia Attfield, Alexandra Lewis, Fatima Cardoso   +5 more
doaj   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

, 2015
Purpose: There is a need to identify more sensitive clinico-pathological criteria to assess the response to Neo-ACT and guide subsequent adjuvant-therapy.
Ball, G., Palmer, D., Pinder, S., MacMilan, RD, Moseley, Paul M., MacMilan, R. D., Pinder, Sarah; id_orcid, Latham, B, Ellis, I., Cornford, Eleanor, Ball, G, Price, James, Moseley, PM, Lee, A. H. S., Ball, Graham, Chan, A, Chan, SYT, Chan, S. Y. T., Abdel-Fatah, TM, Palmer, David, Latham, Bruce, Silverman, R, Moseley, P. M., Chan, Arlene, Palmer, D, Cornford, E, MacMilan, R., Price, J., Chan, A., Cornford, E., Ellis, IO, Abdel-Fatah, Tarek M., Lee, AHS, Ellis, I. O., Pinder, S, Moseley, P., Latham, B., Abdel-Fatah, T. M., Silverman, Rafael, Lee, A., Lee, Andrew H S, MacMilan, R. Douglas, Ellis, Ian O., Chan, Stephen Y T, Silverman, R., Abdel-Fatah, T., Chan, S., Price, J   +47 more
core   +1 more source

HER2 testing in breast cancer: Opportunities and challenges [PDF]

, 2006
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Lebeau, Annette, Annette Lebeau
core   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

The impact of culture and sociological and psychological issues on Muslim patients with breast cancer in Pakistan [PDF]

, 2009
This is a non-final version of an article published in final form in Cancer Nursing, 32(4), 2009. The final published article is available from the link below.Breast cancer is the most common form of cancer in Muslim women in Pakistan.
Banning, M, Zafar, A, Faisal, S, Hassan, M, Hafeez, H   +4 more
core   +1 more source

Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients

Tumor Biology, 2020
This study aimed at investigating the expression of candidate microRNAs (miRs), at initial diagnosis, during neoadjuvant chemotherapy, and after the tumor resection in locally advanced breast cancer patients.
Alaa M Ibrahim, Mahmoud M Said, Amany M Hilal, Amina M Medhat, Ibrahim M Abd Elsalam   +4 more
doaj   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Mechanisms of resistance to lapatinib in HER2 positive breast cancer [PDF]

, 2012
Lapatinib is a tyrosine kinase inhibitor of HER2 which blocks downstream signaling pathways in HER2 positive breast cancer cell lines, tumor xenografts and HER2 positive breast cancer patients.
McDermott, Martina
core